经导管主动脉瓣置换术2023年度进展  

Progress of transcatheter aortic valve replacement in 2023

作　　者：王墨扬 周政 牛冠男 陈阳 丰德京 胡祥铭 史文册 吴永健[1] WANG Mo-yang;ZHOU Zheng;NIU Guan-nan;CHEN Yang;FENG De-jing;HU Xiang-ming;SHI Wen-ce;WU Yong-jian(Department of Cardiology,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China;Department of Cardiology,Peking University People’s Hospital,Beijing 100044,China)

机构地区：[1]国家心血管病中心、北京协和医学院、中国医学科学院阜外医院心内科,北京100037 [2]北京大学人民医院心内科,北京100044

出　　处：《中国介入心脏病学杂志》2024年第1期14-19,共6页Chinese Journal of Interventional Cardiology

基　　金：中国医学科学院临床与转化医学研究专项项目(2022-I2M-C&T-B-044)。

摘　　要：经导管主动脉瓣置换术(TAVR)目前已经成为治疗主动脉瓣疾病患者的有效手段之一,随着技术的不断成熟,器械的持续革新,经验的日益丰富,TAVR的适应证范围得到不断扩展。紧跟国际趋势,我国TAVR手术量逐年稳步上涨。2023年度TAVR领域在低危主动脉瓣狭窄患者中的长期随访结果进一步验证了TAVR手术的远期获益,针对主动脉瓣反流患者行TAVR手术的相关研究以及TAVR手术在二叶式主动脉瓣狭窄患者中的应用均为TAVR适应证的拓展提供了证据支持。与此同时,国内外瓣膜器械的研发及新技术创新层出不穷,全生命周期管理新理念越来越受到重视,尤其是我国本土器械研发进展迅速,多种器械进入临床研究阶段,其临床表现及研究结果值得期待。Transcatheter aortic valve replacement(TAVR)has become one of the eff ective methods for treating patients with aortic valve disease.With the continuous maturity of technology,innovation of instruments and increasing experience,the indications for TAVR has been expanded.Following international trends,the number of TAVR in China has steadily increased with each passing year.In 2023,the long-term follow-up results of TAVR in low-risk AS patients further confirm the long-term benefits of TAVR.The relevant research on TAVR for patients with aortic regurgitation and patients with bicuspid aortic stenosis provide evidence support for the expansion of TAVR indications.At the same time,the development of valve devices and new technological innovations are emerging in an endless stream,and the new concept of full life cycle management is increasingly being valued.Especially in China,the development of local devices is progressing rapidly,and multiple devices have entered the clinical research stage.The clinical manifestations and research results are worth pursuing.

关 键 词：经导管主动脉瓣置换术 适应证 新技术 新器械 进展 

分 类 号：R54[医药卫生—心血管疾病]